GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medincell SA (XPAR:MEDCL) » Definitions » Additional Paid-In Capital

Medincell (XPAR:MEDCL) Additional Paid-In Capital : €30.98 Mil(As of Sep. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Medincell Additional Paid-In Capital?


Medincell's quarterly additional paid-in capital increased from Sep. 2022 (€6.91 Mil) to Mar. 2023 (€7.42 Mil) and increased from Mar. 2023 (€7.42 Mil) to Sep. 2023 (€30.98 Mil).

Medincell's annual additional paid-in capital declined from Mar. 2021 (€75.15 Mil) to Mar. 2022 (€6.91 Mil) but then increased from Mar. 2022 (€6.91 Mil) to Mar. 2023 (€7.42 Mil).


Medincell Additional Paid-In Capital Historical Data

The historical data trend for Medincell's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medincell Additional Paid-In Capital Chart

Medincell Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Additional Paid-In Capital
Get a 7-Day Free Trial 33.15 33.19 75.15 6.91 7.42

Medincell Semi-Annual Data
Mar16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.91 6.91 6.91 7.42 30.98

Medincell Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Medincell Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Medincell's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Medincell (XPAR:MEDCL) Business Description

Traded in Other Exchanges
Address
3 rue des Freres Lumiere, Jacou, FRA, 34830
Medincell SA is a technology-based pharmaceutical firm, aims to optimise the efficiency of medical treatments and make them accessible geographically. The company's product portfolio uses BEPO-patented technology to develop controlled, long-acting injectable medical treatments for a number of therapeutic fields. The firm has a single operating segment: ongoing research and development on processes that use biodegradable polymers to enable the controlled and prolonged release of the active principles of drugs into the human body and animals by means of injection.

Medincell (XPAR:MEDCL) Headlines

No Headlines